Are more courses of immunochemotherapy beneficial for the short‐term outcome of locally advanced esophageal squamous cell carcinoma?

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy and neoadjuvant immunochemotherapy have shown promising results in esophageal carcinoma. However, it is still unclear whether more courses of immunochemotherapy are therapeutically better. We aimed to investigate the safety and efficacy of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuanheng, Su, Xiaodong, Guo, Qiyu, Luo, Guangyu, He, Haoqiang, Cai, Peiqiang, Cai, Muyan, Yue, Haodong, Wang, Zhiqiang, Yang, Guozhen, Lin, Peng, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151135/
https://www.ncbi.nlm.nih.gov/pubmed/36960736
http://dx.doi.org/10.1111/1759-7714.14843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151135/
https://www.ncbi.nlm.nih.gov/pubmed/36960736
http://dx.doi.org/10.1111/1759-7714.14843

Ejemplares similares